1	A proteogenomic analysis of the adiposity colorectal cancer relationship identifies GREM1 as a
2	probable mediator
3	
4	Matthew A Lee ^{1,2;} ,
5	Charlie A Hatcher ^{2,3} ,
6	Emma Hazelwood ²³ ,
7	Lucy J Goudswaard ^{2,3} ,
8	Konstantinos K Tsilidis ^{8,9}
9	Emma E Vincent ^{23,10}
10	Richard M Martin ^{2,3,11}
11	Karl Smith-Byrne ¹²
12	Hermann Brenner ^{13,14,15}
13	Iona Cheng ¹⁶
14	Sun-Seog Kweon ^{17,18}
15	Loic Le Marchand ¹⁹
16	Polly A Newcomb ⁶⁷
17	Robert E Schoen ²⁰
18	Ulrike Peters ⁶⁷
19	Marc J Gunter ¹⁸ ,
20	Bethany Van Guelpen ^{4,5}
21	Neil Murphy ¹
22	
23	1 International Agency for Research on Cancer (IARC/WHO), Nutrition and Metabolism Branch, Lyon, France
24	2 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
25	3 Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK
26	4 Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
27	5 Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden
28	6 Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
29	7 Department of Epidemiology, University of Washington, Seattle, WA, USA
30	8 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
31	9 Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
32	10 School of Translational Health Sciences, University of Bristol, Bristol, UK

- 33 11 National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol and
- 34 Weston NHS Foundation Trust and the University of Bristol, Bristol, UK
- 35 12 Cancer Epidemiology Unit, University of Oxford, Oxford, UK
- 36 13 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg,
- 37 Germany.
- 38 14 Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases
- 39 (NCT), Heidelberg, Germany.
- 40 15 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 41 16 Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, United
- 42 States of America
- 43 17 Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea.
- 44 18 Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, Korea.
- 45 19 University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
- 46 20 Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- 47 48
- 49 "Contributed equally
- 50
- 51 Corresponding author: leem@iarc.who.int
- 52 International Agency for Research on Cancer
- 53 World Health Organisation
- 54 25 avenue Tony Garnier, 69007, Lyon, France

55

57 1. Abstract

- Adiposity is an established risk factor for colorectal cancer (CRC). However, the pathways
 underlying this relationship, and specifically the role of the circulating proteome, is unclear.
- 60

Utilizing two-sample Mendelian randomization and colocalization, based on summary data from large sex-combined and sex-specific genetic studies, we estimated the univariable (UV) associations between: (I) adiposity measures (body mass index, BMI; waist hip ratio, WHR) and overall and site-specific (colon, proximal colon, distal colon, and rectal) CRC risk, (II) adiposity measures and plasma proteins, and (III) adiposity-associated plasma proteins and CRC risk. We used multivariable MR (MVMR) to investigate the potential mediating role of adiposity- and CRC-related proteins in the adiposity-CRC association.

68

69 BMI and WHR were positively associated with CRC risk, with similar associations by anatomical 70 tumour site. 6,591 adiposity-protein (2,628 unique proteins) and 33 protein-CRC (8 unique 71 proteins) associations were identified using UVMR and colocalization. 1 protein, GREM1 was 72 associated with BMI only and CRC outcomes in a manner that was consistent with a potential 73 mediating role in sex-combined and female-specific analyses. In MVMR, adjusting the BMI-CRC 74 association for GREM1, effect estimates were attenuated - suggestive of a potential mediating role 75 - most strongly for the BMI-overall CRC association in women.

76

These results highlight the impact of adiposity on the plasma proteome and of adiposityassociated circulating proteins on the risk of CRC. Supported by evidence from *cis*-SNP UVMR and colocalization analyses, GREM1 was identified as a potential mediator of the BMI-CRC association, particularly in women, and warrants further experimental investigation.

82 2. Introduction

83 Adiposity is an established causal risk factor for the development of colorectal cancer (CRC)¹⁻³. 84 However, the underlying biological pathways are not fully understood. Identifying potentially 85 modifiable mediators of the relationship between adiposity and CRC development could uncover 86 targets for pharmacological and/or lifestyle interventions. Circulating proteins are strong 87 candidate mediators. Evidence from molecular epidemiological and genetic studies has linked 88 adiposity with broad changes in the human circulating proteome, including via effects on glucose 89 and lipid metabolism, and inflammatory and immune markers⁴⁻⁷. Whether these changes to the 90 proteome influence the association between adiposity and CRC risk is unclear.

91

92 Mendelian randomization (MR) uses genetic variants as instrumental variables which, under 93 specific assumptions, can be used to investigate the causal relationship between an exposure and 94 outcome. Given the random allocation of alleles during gametogenesis, across a large enough 95 population, findings of MR analyses are more robust to the effects of confounding and reverse 96 causation than traditional observational studies. Two-step/network MR^{8,9} and Multivariable (MV) 97 MR^{10} analyses can be used to investigate the intermediate effects of traits which may reside on the 98 causal mechanistic pathway from exposure to outcome¹¹. To date, MVMR analyses examining the 99 role of the proteome as an intermediate in the relationship between adiposity and CRC have not 100 been undertaken.

101

Here, we investigated whether circulating proteins act as intermediates in the association between adiposity (BMI and WHR) and CRC risk. We conducted colocalization and MVMR analyses using summary statistics from genome-wide association studies (GWAS) of adiposity

- 105 traits, circulating protein levels, and CRC risk, and examined if mediating proteins were expressed
- 106 in adipose and CRC tissue.

107 3. Methods

108 3.1. Study design

109 Four main analysis steps were performed sequentially (Figure 1) to estimate: (I) the causal 110 relationship between adiposity measures (BMI and WHR) and CRC risk, (II) the causal 111 relationship between adiposity measures and plasma proteins, (III) the causal relationship 112 between proteins and CRC risk, and (IV) the potential mediating effects of adiposity-associated 113 proteins in the adiposity-CRC association. We performed forward and reverse UVMR for steps I-114 III and used MVMR for step IV. For step III we performed cis-SNP UVMR and colocalization. For 115 all steps, sex-combined and sex-specific analyses were performed. All analyses were performed 116 using R version 4.1.2 and the following packages: TwoSampleMR¹² (version 0.4.22), MVMR¹³ 117 (version 0.3), and coloc¹⁴ (version 5.2.0). Forest plots were created using ggforestplot (version 118 0.1.0).



120



Figure 1 Analysis overview. Directed acyclic graph overview of main analyses: I-III; univariable Mendelian randomization analyses, IV; multivariable MR analysis. Text to the right of each analysis gives the requirements for an association. 1-3: MR assumptions; G: genetic variant(s); U: unmeasured confounders; p*: prior probability of a random SNP in the region (1) being (causally associated with trait 1 and not trait 2, (2) trait 2 and not trait 1, or (12) both traits; h4: probability that there is an association with both traits in the region (shared causal variant).

126

127 3.2. Data sources and study populations

128 Details of datasets, study populations, and thresholds used in these analyses are available in 129 Extended Data 1. Briefly, data for adiposity measures were obtained from Pulit et al., (2019)¹⁵; 130 CRC (overall, colon, proximal, distal, and rectal) from Huyghe et al., (2019)¹⁶; and up to 4907 131 plasma proteins from Ferkingstad et al., (2021)¹⁷. BMI and WHR, available in European ancestries (sex-combined and sex-specific), were calculated as $\frac{weight(kg)}{height(m)^2}$ and $\frac{waist circumference(cm)}{hip circumference(cm)}$ 132 133 respectively; CRC, available in European and East Asian ancestries (sex-combined and sex-134 specific), was physician diagnosed; and protein concentrations, available in an Icelandic 135 population (sex-combined), were measured in ethylenediaminetetraacetic acid (EDTA) plasma 136 samples using SomaScan® (SomaLogic, version 4; 4,907 aptamers). The SomaScan platform uses 137 4,034 modified nucleotides known as Slow Off-rate Modified Aptamers (SOMAmers) which make 138 direct contact with proteins, enabling detection of 3,622 unique proteins or protein complexes 139 and quantifies them in relative fluorescence units (RFUs) using DNA microarray¹⁸. Separate 140 SOMAmers can bind to isoforms of the same protein but can also bind to the same protein at 141 different sites (which can be impacted by post-translational modifications or complexes formed 142 with other proteins) enabling a larger number of proteins and protein complexes to be quantified.

143

For all MR analyses, a minimum genome-wide significance threshold of 5 x 10^{-8} was used for all data – more stringent genome-wide significance thresholds were used for adiposity measures and proteins given wider genotyping coverage¹⁹ – and a linkage disequilibrium (LD) independence threshold of 0.001 was used where applicable (Extended Data 1). For all exposures, F-statistics were calculated for each SNP and a mean was calculated for each instrument, with an F-statistic > 10 indicating a strong instrument²⁰. Proteins were included in two UVMR analyses: *cis*- and

150	trans-SNPs were used for reverse MR analyses of the association between adiposity measures and
151	proteins to examine reverse causation; cis-SNPs were used in the forward MR analyses of the
152	association between proteins and CRC.

153

The *cis*-SNPs were obtained directly from the supplementary data of the Ferkingstad et al., paper in which they identified *cis*-SNPs reaching the genome-wide significance threshold (p-value < 1.8 $x \ 10^{-9}$) as those loci which were ≤ 1 Mb from the transcription start site of the gene encoding the measured protein. All SNPs within a 1Mb region of each *cis*-SNP were merged into a single region, and the SNP with the lowest p-value was considered the 'sentinel' variant for that protein. Sentinel variants in LD ($r^2 \geq 0.8$) with one another were considered to be a single 'pQTL variant'. In total, Ferkingstad et al., identified a single *cis*-SNP for 1,490 of 4,907 proteins.

161

162 3.2.1.Units

Data for adiposity and protein measures were inverse rank normally transformed prior to genome-wide analysis. Assuming the distribution of each trait was normal prior to transformation and genome-wide analysis, we interpret these units to be approximately equivalent to a normalized standard deviation (SD) of the respective trait. Estimates and odds ratios (ORs) are therefore interpreted as the change in outcome per normalized SD unit change in the exposure.

168

169 3.3. Statistical analysis

170 MR relies upon three core assumptions: (1) the instrument must be associated with the exposure 171 of interest, (2) there are no confounders of the association between the instrument and the 172 outcome, and (3) the instrument is not related to the outcome except via its effect on the exposure 173 of interest. The same assumptions are extended to include the intermediate in MVMR: (1) the

174 instrument must be associated with the exposure given the presence of the mediator, (2) the 175 instrument must be independent of the outcome given both exposure and mediator, and (3) the 176 instrument is not related to the outcome except via its effect on the exposure given the presence 177 of the mediator. Assumption 1 may be satisfied by using a standard genome-wide significance 178 threshold of 5 x 10⁻⁸ and instruments with an F-statistic, or conditional F-statistic for MVMR 179 analyses²¹, > 10. Assumptions 2 and 3 are unverifiable but were tested using sensitivity models 180 sensitive to the effects of pleiotropy and with cis-SNP UVMR and colocalization. Colocalization 181 attempts to differentiate between distinct causal variants and a single shared signal²². In 182 combination with UVMR, colocalization can be used to assess the validity of MR assumptions 183 (distinct causal variants likely result from LD) and strengthen evidence for a causal effect.

184

185 3.3.1. Identification of associations

186 An adiposity-CRC association (step I) was identified if there was a consistent direction of effect 187 across all MR models and there was no consistent direction of effect in the reverse MR analyses. 188 The same requirement, plus a PhenoSpD23-25 corrected p-value threshold (we used the more 189 conservative of the two approaches applied by PhenoSpD), were used to identify adiposity-190 protein associations (step II). Only proteins with cis-SNP information were used in the 191 subsequent UVMR and MVMR analyses. A protein-CRC association (step III) was identified if the 192 PhenoSpD corrected p-value threshold was met, there was no consistent direction of effect across 193 all MR models in the reverse MR, and evidence of colocalization ($h4 \ge 0.8$) was observed. We 194 interpreted a protein as having a potential mediating role in the adiposity and CRC relationship if 195 the MVMR result adjusting for that protein attenuated towards the null when compared with the 196 UVMR result (step IV).

198 3.3.2. Univariable Mendelian randomization

199 For all exposures, the following summary-level data were obtained from the original GWAS: rsID, 200 effect allele, other/non-effect allele, effect allele frequency, effect estimate, standard error of the 201 effect estimate, p-value, sample size, and units. Genetic variants were extracted from each 202 outcome GWAS and, where these were not present, proxy SNPs were included if LD was ≥ 0.8 . 203 For proxy SNPs, the inclusion of SNPs where the reference strand was ambiguous (strand flips) 204 was allowed and the reference strand was inferred using a minor allele frequency (MAF) 205 threshold so long as the MAF was not \ge 0.3, in which case the proxy SNP was excluded. Exposure 206 and outcome summary statistics for each of the exposure-related SNPs were harmonised in 207 reference to the exposure effect allele being on the increasing scale. For included alleles where 208 the reference strand was ambiguous, the positive strand was inferred using effect allele frequency 209 (EAF) so long as the EAF was not within 0.3 - 0.7, otherwise the SNP was removed.

210

An inverse variance weighted (IVW), multiplicative random effects (IVW-MRE) model was used to estimate the effect of each exposure on the outcome. The model assumes that the strength of the association of the genetic instruments with the exposure is not correlated with the magnitude of the pleiotropic effects and that the pleiotropic effects have an average value of zero²⁶. Where only one SNP was present, the Wald ratio was used (e.g., *cis*-SNP UVMR).

216

217 3.3.2.1.Sensitivity analysis

The assumptions of no pleiotropy among genetic instruments and outcomes were explored using: MR-Egger²⁷, weighted median²⁸, and weighted mode²⁹ based estimators where \ge 3 SNPs were available. MR-Egger provides an estimate of unbalanced or directional horizontal pleiotropy via the intercept of a linear regression of the SNP-exposure and SNP-outcome association²⁷. The

222	weighted median provides consistent estimates when at least 50% of included instruments are
223	invalid ²⁸ . The weighted mode assumes the true causal effect is the most common effect and it is
224	robust when most effect estimates are derived from valid instruments ²⁹ . In addition, a single-SNP
225	MR using the Wald ratio and a "leave-one-out" MR sensitivity analysis were conducted to assess
226	the influence of individual variants on the observed associations.
227	
228	3.3.3. Colocalization
229	For each protein, the sentinel cis-SNP identified by Ferkingstad et al., was extracted along with a
230	1Mb window. This region was then extracted from each CRC GWAS and colocalization was
231	implemented using the single causal variant approach of Giambartolomei et al., (2014) ³⁰ . The LD

For each protein, the sentinel cis-SNP identified by Ferkingstad et al., was extracted along with a 1Mb window. This region was then extracted from each CRC GWAS and colocalization was implemented using the single causal variant approach of Giambartolomei et al., $(2014)^{30}$. The LD matrix was generated using the 1000 genomes reference panel (phase 3) and priors were set at p¹ = 10⁻⁶, p² = 10⁻⁶, and p¹² = 10⁻⁷ based on a window of 5,000 SNPs using https://chr1swallace.shinyapps.io/coloc-priors/ (accessed 15/05/2023).

235

236 3.3.4. Multivariable Mendelian randomization

SNPs associated with the exposure (adiposity) and proposed intermediate proteins (*cis-* and *trans-*SNPs) were extracted and combined. This combined SNP list was extracted from the adiposity GWAS. The resulting instrument was then clumped to remove duplicate SNPs and SNPs in LD with one another using the same clumping thresholds as with the UVMR analysis. An IVW model was used to obtain the direct causal effect of each adiposity measure adjusted for each protein on CRC risk. Instrument strength for each exposure was estimated using a generalized version of Cochran's Q³¹ assuming a pairwise covariance of zero¹³.

245 3.3.5. Protein expression analyses

- 246 To investigate whether proteins included in the MVMR analyses were expressed in adipose and
- 247 CRC tissue we used GTEx³² (version 8) data to compare protein tissue expression relative to whole
- 248 blood using the Wilcoxon rank sum test and visualised expression profiles using violin plots.

250 4. Results

251	An overview of the datasets used, protein information, and all results from the MR and
252	colocalization analyses are presented in Extended Data 1. PhenoSpD identified a total of 1,293
253	independent variables, and a PhenoSpD corrected p-value threshold of 3.97 x 10^{-5} was, therefore
254	used (Extended Data 2).
255	
256	4.1. Association between adiposity measures and colorectal cancer
257	In step I, BMI and WHR were positively associated with overall and site-specific CRC risk in men
258	and women (Figure 2). Sensitivity models were broadly consistent (directions of effect estimates
259	were in the same direction as the IVW-MRE model and CIs overlapped) with the main IVW-
260	MRE model. However, inconsistent directions were observed for the association between WHR
261	and distal colon cancer and overall CRC in men and rectal cancer in women (Extended data 3).
262	Furthermore, the reverse UVMR analyses (Extended data 4) showed an increasing effect of
263	proximal and distal colon cancer on WHR. In both cases, sensitivity analyses produced generally
264	consistent results, particularly for proximal colon cancer in men and for distal colon cancer in
265	women. These pairings were, therefore, excluded from subsequent MVMR analyses.



267 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7
 268 Figure 2 Association between adiposity measures and colorectal cancer outcomes. Odds ratios and 95% confidence intervals shown for the main analysis using the inverse variance weighted multiplicative random effects (IVW-MRE). BMI = body mass index; WHR = waist hip ratio

271

4.2. Association between adiposity measures and proteins



278 reaching the PhenoSpD-corrected p-value threshold in the female analysis compared to the male

analysis (Figure 4).



Figure 3 Overview of associations between adiposity measures and plasma proteins (step II in the main analysis plan). Arrows show the direction of the univariable Mendelian randomization (UVMR) analysis. Values on the outside of the lines indicate the number of associations identified in that direction; values in between the lines indicate the number of associations identified in both directions and for which there is, therefore, conflicting evidence of association. N = gives the number of proteins available for analysis. BMI- WHR-associated gives the number of proteins associated with the adiposity measure. BMI = body mass index; WHR = waist hip ratio.

288



289

adiposity-protein associations

Figure 4 Association between adiposity measures and proteins in step II of the main analysis plan. The volcano plot shows effect estimates and -log10(pval). Adiposity-protein associations are highlighted in purple (analyses reaching the PhenoSpD corrected p-value (0.05/1293), consistent directions of effect across MR models, and no conflicting association identified in the reverse UVMR). Protein labels highlight those proteins which were associated with colorectal cancer outcomes in the UVMR analysis in step III of the main analysis plan. BMI = body mass index; WHR = waist hip ratio.

295

4.3. Association between proteins and colorectal cancer

297 In step III, it was possible to perform UVMR analysis of up to 962 proteins in relation to CRC

298 outcomes using *cis*-SNPs. In total, 35 protein-CRC (8 unique proteins) associations were identified

299 (PhenoSpD-corrected p-value threshold reached and no conflicting association identified in the

300 reverse UVMR; Figure 5) across the sex-combined and sex-specific UVMR analyses. In the male-301 specific analyses, 65 reverse associations were identified between proteins and distal colon cancer 302 risk. However, there were no conflicts with the forward UVMR analysis in this or any other 303 protein-CRC analyses. There was evidence ($h_4 \ge 0.8$) of colocalization for 87 protein-CRC pairs 304 (25 unique proteins) across the sex-combined and sex-specific analyses of the CRC outcomes 305 (Extended Data 4). Of the 35 protein-CRC UVMR associations, 2 were not corroborated by 306 colocalization (h4 < 0.5 for the protein GRFAL in relation to overall CRC and rectal cancer risk in 307 sex-combined analysis).



310Figure 5 Overview of associations between proteins and colorectal cancer (CRC) outcomes (step III in the main analysis311plan). Arrows show the direction of the univariable Mendelian randomization (UVMR) analysis. Values on the outside of the312lines indicate the number of associations identified in that direction; values in between the lines indicate the number of313associations identified in that direction; values in between the lines indicate the number of314number of proteins available for analysis. MR = gives the number of cis-SNP UVMR analyses which reached the PhenoSpD315pvalue threshold for that analysis. Colocalization = gives the number of proteins which colocalized with that CRC outcome.316MR + colocalization = gives the overlap between the cis-SNP UVMR and colocalization analyses and indicates the protein-317CRC associations.



319

320
321
321
322Figure 6 Association between adiposity-related proteins and colorectal cancer (CRC) outcomes in step III of the main
analysis plan. The volcano plot shows effect estimates and -log10(pval) with analyses reaching the PhenoSpD corrected p-
value (0.05/1293) highlighted in blue and analyses reaching the PhenoSpD corrected-pvalue and with evidence of
colocalization labelled with the protein name. The X-axis has been constrained to -3 - 3, excluding 3 analyses which did not
meet any association thresholds: PTP4A2 and proximal colon cancer in males (effect estimate = 102) and NANS and distal
colon cancer in males (effect estimate = 19) and females (effect estimate = 19).

326

327 4.4. Multivariable Mendelian randomization

Of the 7 proteins associated with CRC outcomes across the sex-combined and sex-specific analyses, the results for only 1 (GREM1) were directionally consistent with a possible mediating role of the association between adiposity and CRC risk. That is, an increase in BMI was associated

331	with an increase in GREM1 and an increase in GREM1 was associated with an increase in CRC
332	risk. In MVMR (step IV) we considered a protein as having a potential mediating role if, in
333	comparison to the UVMR estimate of the association between adiposity and CRC, the adjusted
334	estimate was attenuated (i.e., the effect estimate tends towards the null and the CI overlaps the
335	null). For GREM1, effect estimates and CIs for all MVMR analyses tended towards the null.
336	However, evidence of attenuation was observed solely for the female-specific analysis of overall
337	CRC risk (Figure 7). Attenuation of the sex-combined analysis of rectal CRC was also observed,
338	but the CI of the UVMR effect of BMI on rectal cancer risk also overlapped the null. Conditional
339	F-statistics were > 10 (Extended Data 4). There was evidence that all but the female-specific
340	analysis of distal colon cancer used invalid instruments (Q statistic p-value < 0.05).



342

Figure 7 Association between body mass index (BMI) and colorectal cancer outcomes using univariable (UV; orange line) and multivariable (MV; red lines) Mendelian randomization (MR). In these MVMR analyses (step IV), the effect of BMI on colorectal cancer outcomes is estimated after adjusting for the effect of GREM1. Odds ratios for the inverse variance weighted multiplicative random effects model shown alongside 95% confidence intervals. No adiposity-protein-CRC associations were identified in the male UVMR analyses and as such MVMR was not performed.

348

349 4.1. Follow-up analysis

350 Using GTEx data, GREM1 was found to be differentially expressed (Bonferroni corrected p-value

351 = 0.05/53) in most tissues compared to whole blood, with some of the highest levels noted in the

352 gastrointestinal tract and visceral adipose tissue in both sexes (Figure 8).



Figure 8 Tissue gene expression profile of GREM1. The violin plot presents expression levels as log transcripts per million (TPM). Data are from GTEx version 8^{32} . Box plots are shown with the interquartile range (25^{th} and 75^{th} percentiles).

- 355 356 357
- Colours distinguish different tissue types (e.g., adipose and brain).

358

359 5. Discussion

Using complementary MR and colocalization analyses we conducted the largest and most comprehensive study to date examining the role of the plasma proteome as an intermediate in the relationship between adiposity and CRC development. We found novel evidence of a potential mediating role of the protein GREM1, primarily in the association between BMI and overall CRC risk in women. For the remainder of our analyses, we found little evidence of individual proteins acting as intermediates in the adiposity-CRC relationship.

366

367 GREM1, a bone morphogenic protein (BMP) antagonist³³, has previously been linked with 368 CRC^{16,17,34,35}, and is expressed in many tissues, including adipose and colon tissue. BMPs play an 369 important role in embryonic development and morphogenesis and may be considered tumour 370 repressors as inhibition of BMP signalling has been associated with a number of cancers^{36,37}. 371 GREM1 is associated with proliferation, angiogenesis, and epithelial-to-mesenchymal transition 372 of cancer cells³⁶ and may be involved in colon cancer tumour progression³⁸, with a number of 373 studies linking GREM1 to CRC development^{34,35,39}. In addition, a recent gene-environment 374 interaction analysis identified a locus in the FMN1/GREM1 gene region that interacted with BMI 375 on the positive association with CRC risk⁴⁰. The exact mechanisms underlying the GREM1-CRC 376 relationship are unclear but may be related to expression in the tumour microenvironment given 377 that GREM1 expression is lower in CRC tissue than adjacent non-cancerous and normal tissue³⁴. 378 Increased GREM1 expression in CRC tissue has also been associated with low tumour stage and a 379 more favourable prognosis⁴¹, and increased GREM1 expression is found in the tumour 380 microenvironment, such as in visceral adipose tissue42 and colonic crypt bases via cancer 381 associated fibroblasts43.

383 To our knowledge, this was the first comprehensive proteogenomic analysis conducted so far to 384 estimate the role of the plasma proteome as an intermediate of the positive association found 385 between adiposity and CRC. Our study has several additional notable strengths. Adiposity-386 protein-CRC triples included in the MVMR analyses were supported by consistent directions of 387 effect across the main IVW-MRE model and sensitivity models (MR-Egger, weighted median, and 388 weighted mode). We also conducted reverse UVMR analyses for all adiposity-CRC, adiposity-389 protein, and protein-CRC analyses to identify possible reverse causation and exclude pairs where 390 evidence was conflicting. Several limitations should also be acknowledged. Although the 391 availability of sex-specific summary statistics from large genome-wide association studies were 392 available for adiposity measures and CRC, only sex-combined protein data were available which 393 may have led to biased estimates, especially for some of the MVMR analyses, in which the 394 adiposity exposure and outcome were both sex-specific. Instrument strength, measured via F-395 statistics, was appropriate for most analyses, including the MVMR analyses. However, there was 396 evidence of weak instrument bias across most MVMR analyses which can lead to estimates for the 397 exposure and intermediate moving towards and away from the null¹³. In addition, *cis*-SNPs 398 identified by Ferkingstad et al., were available for less than half of the 4,907 proteins included in 399 the adiposity-protein UVMR analysis.

400

401 Our results highlight the broad impact of adiposity on the plasma proteome and of adiposity-402 associated circulating proteins on the risk of developing CRC. We found robust evidence of a 403 causal effect of one adiposity-related protein, GREM1, as a likely mediator of the adiposity and 404 CRC relationship, particularly for women. Given evidence from previous studies highlighting the 405 relationships between GREM1 and CRC, our results suggest that the GREM1 pathway may be a

406 potential mechanism underlying the obesity-CRC relationship and future experimental

407 investigation is warranted.

409 6. Author contributions

- 410 MAL: Data curation, Formal analysis, Investigation, Methodology, Project administration,
- 411 Visualisation, Writing original draft, Writing review and editing
- 412 CAH: Methodology, Writing review and editing
- 413 EH: Methodology, Writing review and editing
- 414 LG: Writing review and editing
- 415 UP: Writing review and editing
- 416 KKT: Writing review and editing
- 417 EEV: Writing review and editing
- 418 RMM: Writing review and editing
- 419 MJG: Conceptualization, Funding acquisition, Methodology, Project administration, Resources,
- 420 Supervision, Writing review and editing
- 421 HB: Writing review and editing
- 422 IC: Writing review and editing
- 423 SK: Writing review and editing
- 424 LLM: Writing review and editing
- 425 PAN: Writing review and editing
- 426 RES: Writing review and editing
- 427 BVG: Conceptualization, Funding acquisition, Methodology, Project administration, Resources,
- 428 Supervision, Writing review and editing
- 429 NM: Conceptualization, Funding acquisition, Methodology, Project administration, Resources,
- 430 Supervision, Writing review and editing
- 431

- 432 7. Conflict of interest
- 433 None declared.
- 434

435 8. Acknowledgements & Funding

436 Funding (IIG FULL 2021 030) was obtained from Wereld Kanker Onderzoek Fonds (WKOF), as 437 part of the World Cancer Research Fund International grant programme, and Cancer Research 438 UK (C18281/A29019). NM is supported by the French National Cancer Institute (INCa SHSESP20, 439 grant No. 2020-076). BVG is supported by the Swedish Cancer Society (fellowship No. 21 0467 FE 440 01 H and project grant No. 20 1154 PjF). EH is supported by a Cancer Research UK Population 441 Research Committee Studentship (C18281/A30905 and is part of the Medical Research Council 442 Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical 443 Research Council (MC_UU_00032/03) and the University of Bristol. LJG is supported by a 444 Transition Fellowship as part of the British Heart Foundation Accelerator Award (AA/18/1/34219) 445 and an Academic Career Development Fund (University of Bristol). RMM is a National Institute 446 for Health Research Senior Investigator (NIHR202411). RMM is supported by a Cancer Research 447 UK 25 (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). 448 RMM is also supported by the NIHR Bristol Biomedical Research Centre which is funded by the 449 NIHR (BRC-1215-20011) and is a partnership between University Hospitals Bristol and Weston 450 NHS Foundation Trust and the University of Bristol. RMM is affiliated with the Medical Research 451 Council Integrative Epidemiology Unit at the University of Bristol which is supported by the 452 Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and 453 MC_UU_00011/4) and the University of Bristol. Department of Health and Social Care disclaimer:

454 The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or

455 the Department of Health and Social Care.

456

457 9. Disclaimer

458 Where authors are identified as personnel of the International Agency for Research on 459 Cancer/World Health Organization, the authors alone are responsible for the views expressed in 460 this article and they do not necessarily represent the decisions, policy or views of the 461 International Agency for Research on Cancer/World Health Organization.

462

463 10. Data availability

464 10.1.Underlying data

465 This work is supported by а GitHub repository 466 (https://github.com/mattlee821/adiposity_proteins_colorectal_cancer) which is archived on 467 Zenodo (https://zenodo.org/record/7780822#.ZCO3U-xBz0o). Here, all publicly available data, 468 code, and results used in this work are available. The full summary statistics for BMI and WHR 469 are publicly available from Zenodo (https://zenodo.org/record/1251813#.Yk7O25PMIUE). The full 470 all publicly DECODE summary statistics for proteins are available from 471 (https://download.decode.is/form/folder/proteomics). The full summary statistics for CRC are not 472 publicly available but can be obtained from GECCO 473 (https://www.fredhutch.org/en/research/divisions/public-health-sciences-474 division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-

475 <u>gecco.html</u>).

477 10.2.Extended Data

- 478 This project contains the following extended data available from Zenodo 479 <u>https://zenodo.org/record/7780822#.ZCQ3U-xBz0o</u>):
- 480

481 Extended data 1 is an Excel file of 8 tables:

482 1. Overview of all data used, including doi of source. Columns: N = overall sample size or case 483 sample size; pvalue_threshld = genome-wide significance threshold used to identify associated 484 single nucleotide polymorphisms (SNPs); $LD_r2 = linkage$ disequilibrium independence threshold; 485 LD_window = LD independence base window; SNPs = associated SNPs identified using pvalue 486 and LD thresholds; $f_{stat} = mean f_{statistics}$ for the associated SNPs; measure = how the trait was 487 measured in the source; adjustment = how the trait was adjusted during genome-wide analysis; 488 transformation = transformation of the trait prior to genome-wide analysis; unit = how the trait is 489 expressed given the transformation.

490

491 2. Extended information on proteins sourced from Ferkingstad et al.

492

3. All publicly available exposure data used in Mendelian randomization analyses – this does not
include colorectal cancer data. Columns: CHR = chromosome; POS = base position; SNP = rsID;
eaf.exposure = effect allele frequency; beta.exposure = effect estimate; se.exposure = standard error
of the beta; pval.exposure = pvalue of the effect estimate and standard error.

497

498 4-8. All results produced in the Mendelian randomization (MR) and colocalization analyses, split

499 by analysis: adiposity-cancer, adiposity-protein, protein-cancer, colocalization, multivariable MR.

500 Columns: nsnp = number of SNPs used for the exposure instrument; b = effect estimate; se =

501	standard error; pval = pvalue of the effect estimate and standard error; forward always refers to
502	column 1 as the exposure and column 2 as the outcome; reverse always refers to column 2 as the
503	exposure and column 1 as the outcome; Qstat/Qpval = Cochranes Q statistic and associated pvalue;
504	fstat_adiposity/fstat_protein = the F-statistic associated with adiposity and protein instrument
505	used in the analysis; nsnp_colocalization = number of SNPs included in the 1Mb window used for
506	colocalization; $h0-4 = hypothesis priors; h0 = neither trait has a genetic association in the region;$
507	h1 = only trait 1 has a genetic association in the region; $h2 = only trait 2$ has a genetic association
508	in the region; $h3 = both$ traits are associated, but with different causal variants; $h4 = both$ traits are
509	associated and share a single causal variant.
510	
511	Extended data 2. PhenoSpD results. File gives the eigenvalue associated with each factor in the
512	correlation matrix and the variance of these values. We use the effective number of independent
513	variables calculated using the method of Li and Ji (2005) ²⁵ .
514	Extended data 3. Association between adiposity measures and colorectal cancer outcomes. Effect
515	estimates and 95% confidence intervals shown for the main analysis using the inverse variance
516	weighted multiplicative random effects (IVW-MRE) model and 3 sensitivity models. BMI = body
517	mass index; WHR = waist hip ratio.
518	
519	Extended data 4. Association between colorectal cancer measures and adiposity measures. Effect
520	estimates and 95% confidence intervals shown for the main analysis using the inverse variance
521	weighted multiplicative random effects (IVW-MRE) model and 3 sensitivity models. BMI = body
522	mass index; WHR = waist hip ratio.

523

524 Extended data 5. STROBE-MR checklist^{44,45}

525

527 11. References

528	1.	Lee, M. et al. Systematic review and meta-analyses: What has the application of
529		Mendelian randomization told us about the causal effect of adiposity on health outcomes?
530		[version 1; peer review: awaiting peer review]. Wellcome Open Res. 7, (2022).
531	2.	Bull, C. J. et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian
532		randomization study. BMC Med. 18, 396 (2020).
533	3.	Lauby-Secretan, B. et al. Body Fatness and Cancer — Viewpoint of the IARC Working
534		Group. N. Engl. J. Med. 375, 794–798 (2016).
535	4.	Goudswaard, L. J. et al. Effects of adiposity on the human plasma proteome:
536		observational and Mendelian randomisation estimates. Int. J. Obes. 2005 45, 2221-2229
537		(2021).
538	5.	Kibble, M. <i>et al.</i> An integrative machine learning approach to discovering multi-level
539		molecular mechanisms of obesity using data from monozygotic twin pairs. R. Soc. Open
540		Sci. 7, 200872 (2022).
541	6.	Rajan, M. R. et al. Comparative analysis of obesity-related cardiometabolic and renal
542		biomarkers in human plasma and serum. Sci. Rep. 9, 15385 (2019).
543	7.	Zaghlool, S. B. <i>et al.</i> Revealing the role of the human blood plasma proteome in obesity
544		using genetic drivers. Nat. Commun. 12, 1279 (2021).
545	8.	Burgess, S., Daniel, R. M., Butterworth, A. S., Thompson, S. G. & Consortium, EI.
546		Network Mendelian randomization: using genetic variants as instrumental variables to
547		investigate mediation in causal pathways. Int. J. Epidemiol. 44, 484–495 (2015).
548	9.	Relton, C. L. & Davey Smith, G. Two-step epigenetic mendelian randomization: A
549		strategy for establishing the causal role of epigenetic processes in pathways to disease.
550		Int. J. Epidemiol. (2012) doi:10.1093/ije/dyr233.
551	10	. Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of
552		multivariable Mendelian randomization in the single-sample and two-sample summary
553		data settings. Int. J. Epidemiol. 48, 713-727 (2019).
554	11	. Carter, A. R. et al. Mendelian randomisation for mediation analysis: current methods and
555		challenges for implementation. Eur. J. Epidemiol. 36, 465–478 (2021).
556	12	. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the
557		human phenome. <i>eLife</i> 7 , e34408 (2018).
558	13	. Sanderson, E., Spiller, W. & Bowden, J. Testing and correcting for weak and pleiotropic
559		instruments in two-sample multivariable Mendelian randomization. Stat. Med. n/a,
560		(2021).
561	14	. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
562		colocalisation analyses. PLOS Genet. 16, e1008720 (2020).
563	15	. Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat
564		distribution in 694 649 individuals of European ancestry. Hum. Mol. Genet. 28, 166–174
565		(2019).
566	16	. Huyghe, J. R. et al. Discovery of common and rare genetic risk variants for colorectal
567		cancer. Nat. Genet. 51, 76–87 (2019).
568	17	. Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and
569		disease. Nat. Genet. 53, 1712–1721 (2021).
570	18	. Rohloff, J. C. et al. Nucleic Acid Ligands With Protein-like Side Chains: Modified
571		Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol. Ther. Nucleic Acids
572		3 , e201 (2014).
573	19	. Pulit, S. L., de With, S. A. J. & de Bakker, P. I. W. Resetting the bar: Statistical
574		significance in whole-genome sequencing-based association studies of global
575		populations. <i>Genet. Epidemiol.</i> 41 , 145–151 (2017).

576	20.	Haycock, P. C. et al. Best (but oft-forgotten) practices: The design, analysis, and
577		interpretation of Mendelian randomization studies. Am. J. Clin. Nutr. 103, (2016).
578	21.	Sanderson, E. & Windmeijer, F. A weak instrument [Formula: see text]-test in linear IV
579		models with multiple endogenous variables. J. Econom. 190, 212–221 (2016).
580	22.	Zuber, V. et al. Combining evidence from Mendelian randomization and colocalization:
581		Review and comparison of approaches. Am. J. Hum. Genet. 109, 767–782 (2022).
582	23.	Zheng, J. et al. PhenoSpD: an integrated toolkit for phenotypic correlation estimation and
583		multiple testing correction using GWAS summary statistics. <i>GigaScience</i> 7, (2018).
584	24.	Nyholt, D. R. A simple correction for multiple testing for single-nucleotide
585		polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74, 765–
586		769 (2004).
587	25.	Li, J. & Ji, L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a
588		correlation matrix. Heredity 95, 221–227 (2005).
589	26.	Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
590		imprecisely measured traits using GWAS summary data. PLOS Genet. 13, e1007081
591		(2017).
592	27.	Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
593		instruments: effect estimation and bias detection through Egger regression. Int. J.
594		<i>Epidemiol.</i> 44 , 512–525 (2015).
595	28.	Burgess, S. et al. Dissecting Causal Pathways Using Mendelian Randomization with
596		Summarized Genetic Data: Application to Age at Menarche and Risk of Breast Cancer.
597		<i>Genetics</i> 207 , 481–487 (2017).
598	29.	Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data
599		Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol
600		(2017) doi:10.1093/ije/dyx102.
601	30.	Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
602		Association Studies Using Summary Statistics. PLOS Genet. 10, e1004383 (2014).
603	31.	Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of
604		multivariable Mendelian randomization in the single-sample and two-sample summary
605		data settings. Int. J. Epidemiol. 48, 713–727 (2018).
606	32.	THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects
607		across human tissues. Science 369, 1318–1330 (2020).
608	33.	GREM1 gremlin 1, DAN family BMP antagonist [Homo sapiens (human)] - Gene -
609		NCBI. https://www.ncbi.nlm.nih.gov/gene/26585.
610	34.	Jang, B. G. et al. Prognostic significance of stromal GREM1 expression in colorectal
611		cancer. Hum. Pathol. 62, 56-65 (2017).
612	35.	Li, R. et al. Gremlin-1 Promotes Colorectal Cancer Cell Metastasis by Activating ATF6
613		and Inhibiting ATF4 Pathways. Cells 11, 2136 (2022).
614	36.	Park, SA. Role of Gremlin-1 in Cancer. Biomed. Sci. Lett. 24, 285–291 (2018).
615	37.	Bach, DH., Park, H. J. & Lee, S. K. The Dual Role of Bone Morphogenetic Proteins in
616		Cancer. Mol. Ther. Oncolytics 8, 1–13 (2018).
617	38.	Karagiannis, G. S. et al. Bone morphogenetic protein antagonist gremlin-1 regulates
618		colon cancer progression. Biol. Chem. 396, 163-183 (2015).
619	39.	Li, J. et al. A functional variant in GREM1 confers risk for colorectal cancer by
620		disrupting a hsa-miR-185-3p binding site. Oncotarget 8, 61318–61326 (2017).
621	40.	Aglago, E. K. et al. A genetic locus within the FMN1/GREM1 gene region interacts with
622		body mass index in colorectal cancer risk. Cancer Res. CAN-22-3713 (2023)
623		doi:10.1158/0008-5472.CAN-22-3713.

- 41. Gremlin1 expression associates with serrated pathway and favourable prognosis in
 colorectal cancer Pelli 2016 Histopathology Wiley Online Library.
- 626 https://onlinelibrary.wiley.com/doi/abs/10.1111/his.13006.
- 42. The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2
 Diabetes and NAFLD/NASH | Diabetes | American Diabetes Association.
- https://diabetesjournals.org/diabetes/article/69/3/331/39768/The-Novel-Adipokine Gremlin-1-Antagonizes-Insulin.
- 43. Dutton, L. R. *et al.* Fibroblast-derived Gremlin1 localises to epithelial cells at the base of
 the intestinal crypt. *Oncotarget* 10, 4630–4639 (2019).
- 44. Skrivankova, V. W. *et al.* Strengthening the reporting of observational studies in
 epidemiology using mendelian randomisation (STROBE-MR): explanation and
 elaboration. *BMJ* 375, n2233 (2021).
- 45. Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in
 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA*326, 1614–1621 (2021).
- 638 639
- 640